Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GSK forms collaboration with Angiochem around lysosomal storage disorders

Executive Summary

Angiochem Inc. (drug candidates capable of crossing the blood-brain barrier) has agreed to generate and develop for GlaxoSmithKline PLC an enzyme replacement therapy for an unspecified lysosomal storage disorder (LSD). GSK may expand the agreement to other LSDs, a group of rare inherited metabolic diseases caused by enzyme deficiencies that lead to build-up of toxic materials in the cells.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies